EVENT DOSSIER
On September 8, 2026, “Nature News” reported that two tragic cases of children dying due to gene therapy occurred in China recently. These incidents have sparked widespread discussions among the international community regarding the safety, ethical guidelines, and regulatory mechanisms of gene therapy. Currently, relevant authorities are seeking lessons from these incidents to explore future development directions, aiming to balance innovation with risk management.
两名儿童在中国基因编辑试验中死亡，引发对监管及中国生物医药行业声誉的担忧。上海汇华基因公司宣布一名男孩于 2025 年 8 月 5 日在试验中去世；另一起由上海交通大学和新华医院主导的试验中，一名六岁女孩于去年三月因 CHD3 基因突变导致的 Snijders Blok–Campeau 综合征死亡。研究人员称这两起事件涉及伦理违规且缺乏透明度，并可能促使中国政府加强基因疗法试验法规或收紧“研究者发起试验”监管。此前政府曾对贺建奎 2018 年违规实验实施严厉处罚，但此次涉事科学家被视为成功学者，其机构未回应媒体关于调查的提问。